Entyvio is for intravenous use only. It is to be reconstituted and further diluted prior to intravenous administration.
Entyvio is administered as an intravenous infusion over 30 minutes. Patients should be monitored during and after infusion. For the first two infusions, they should be observed for approximately two hours following completion of the infusion for signs and symptoms of acute hypersensitivity reactions. For all subsequent infusions, patients should be observed for approximately one hour following completion of the infusion.
Vedolizumab Reconstitution and Administration Video